STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #680 by analyst upside · 2026-08-14
ZVRA
Zevra Therapeutics, Inc.
Healthcare · Market Cap $664M · P/E 12.0x
ANALYST PRICE TARGET
+123.6%
implied upside to consensus target
Current Price $11.18
Consensus Target $25.0
Bull Target $35.0
Bear Target $20.0
Analysts Covering 9
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
7
Hold
0
Sell
0
52-Week Low $7.16
52-Week High $15.04
YTD Return +34.1%
FUNDAMENTALS
Market Cap $664M
P/E Ratio (TTM) 12.0x
Forward P/E 10.6x
EPS (TTM) $0.93
PEG Ratio 10.67
Dividend Yield N/A
Revenue (TTM) $136M
Profit Margin 42.8%
52-WEEK RANGE
52-Week Low $7.16
52-Week High $15.04
Current Price $11.18
Bear Target $20.0
Bull Target $35.0
● Now $11.18 ● Target $25.0
TRADING DATA
Avg Volume 1.8M
YTD Return +34.1%
Analyst Count 9
Consensus Buy
Upside to Target +123.6%
Last Updated 2026-08-14

ANALYST SUMMARY

Zevra Therapeutics, Inc. (ZVRA) is currently trading at $11.18 with a Wall Street consensus price target of $25.0, implying potential upside of 123.6% over the next 12 months. 9 analysts currently cover ZVRA, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $35.0, while the most cautious has a target of $20.0.

ZVRA operates in the Healthcare sector with a market capitalisation of $664M. The stock is up 34.1% year-to-date and is currently trading near the upper end of its 52-week range of $7.16 – $15.04.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for ZVRA, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Canaccord Genuity - Reiterated
Buy → Buy 2026-06-11 Building track record
Maxim Group - Reiterated
Buy → Buy 2026-06-10 28% win rate (40 calls)
Guggenheim - Reiterated
Buy → Buy 2026-06-10 62% win rate (8 calls)
BTIG reit
Buy → Buy 2026-06-09 38% win rate (8 calls)
Canaccord Genuity - Reiterated
Buy → Buy 2026-06-09 Building track record
Citizens - Reiterated
Market Outperform → Market Outperform 2026-06-09 Building track record
Cantor Fitzgerald - Reiterated
Overweight → Overweight 2026-06-08 40% win rate (10 calls)
Guggenheim - Reiterated
Buy → Buy 2026-05-08 62% win rate (8 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
48
out of 100
Coverage depth
18/30
Consensus clarity
3/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →